Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

医学 托法替尼 溃疡性结肠炎 安慰剂 优势比 内科学 置信区间 随机化 随机对照试验 人口 英夫利昔单抗 外科 类风湿性关节炎 疾病 替代医学 环境卫生 病理
作者
Arshdeep Singh,Manjeet K Goyal,Vandana Midha,Ramit Mahajan,K. Kaur,YK Gupta,Dharmatma Singh,Namita Bansal,Ramandeep Kaur,Shivam Kalra,Omesh Goyal,Varun Mehta,Ajit Sood
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
被引量:7
标识
DOI:10.14309/ajg.0000000000002635
摘要

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭应助GC采纳,获得10
2秒前
renhu发布了新的文献求助10
2秒前
KAI完成签到,获得积分10
2秒前
Hello应助zyy采纳,获得30
3秒前
蓝桉完成签到,获得积分10
3秒前
KAI发布了新的文献求助10
4秒前
6秒前
7秒前
怪胎完成签到,获得积分10
7秒前
赘婿应助将将采纳,获得10
7秒前
7秒前
小夜完成签到,获得积分10
8秒前
琪qi发布了新的文献求助10
8秒前
Monologue完成签到 ,获得积分10
10秒前
nuoni完成签到 ,获得积分10
11秒前
11秒前
柳易槐发布了新的文献求助30
12秒前
12秒前
minion发布了新的文献求助10
12秒前
方半仙完成签到,获得积分10
12秒前
13秒前
vicluwang完成签到,获得积分10
13秒前
小屁孩完成签到,获得积分0
13秒前
14秒前
tzq发布了新的文献求助10
16秒前
17秒前
alex发布了新的文献求助10
17秒前
liuqi完成签到 ,获得积分10
17秒前
18秒前
浅尝离白给咕噜噜的求助进行了留言
19秒前
Fengliguantou发布了新的文献求助10
19秒前
20秒前
未语的阳光完成签到 ,获得积分10
20秒前
20秒前
20秒前
21秒前
23秒前
橘子汽水发布了新的文献求助10
23秒前
吃鱼鱼鱼完成签到,获得积分10
23秒前
香饽饽发布了新的文献求助10
23秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138062
求助须知:如何正确求助?哪些是违规求助? 2789039
关于积分的说明 7789616
捐赠科研通 2445478
什么是DOI,文献DOI怎么找? 1300354
科研通“疑难数据库(出版商)”最低求助积分说明 625902
版权声明 601046